ANALYTICAL METHODS FOR THE DETERMINATION OF VALSARTAN IN MEDICINAL PRODUCTS
(LITERATURE REVIEW)
DOI:
https://doi.org/10.11603/mcch.2410-681X.2023.i1.13746Keywords:
Valsartan, high performance liquid chromatography with UV detection, absorption spectrophotometry, quantification, tablets, capsules, dosage formsAbstract
Introduction. Valsartan belongs to the group of antihypertensive drugs, an angiotensin II receptor blocker. It is used to treat hypertension, post-infarction conditions and chronic heart failure. Valsatran has been available on the pharmaceutical market for more than 25 years and, despite such a long time, has not lost its clinical efficacy compared to more modern representatives of this group of drugs. Cardiologists note the effectiveness of Valsartan in the treatment of hypertension both as monotherapy and in combination with other antihypertensive drugs.
The aim of the study – to analyze the scientific literature on the development and validation of analytical methods for the determination of valsatrite in substances and medicinal products, to summarize the information obtained, to identify the advantages and disadvantages of existing methods of analysis.
Research Methods. The information was analyzed using PubMed, PubChem, ScienceDirect, the State Pharmacopoeia of Ukraine, the European Pharmacopoeia and scientific literature.
Results and Discussion. Information on the goals, objectives, features of the study, complications arising during the development and validation of analytical methods for the determination of Valsartan in medicines is summarized. The study is of practical importance for modern pharmaceutical analysis, if the task is to develop analytical methods for the determination of valsartan in mono-formulations, the analyst can use UV-visible spectrophotometry and HPLC. If the objective is to develop analytical methods for the determination of Valsartan in binary combinations, the analyst should consider the effects of the other APIs in the combination. When the analysis shows that the other APIs do not interfere with the analysis, UV-visible spectrophotometry and HPLC should be preferred. When other APIs do interfere with the results, HPLC should be used to develop new methods for analysis.
Conclusions. The analysis of existing methods for the determination of Valsartan showed that the most commonly used methods are HPLC and UV-visible spectrophotometry. In most cases, methods for the identification and quantification of Valsartan in mono preparations and binary combinations with other APIs are described. However, these methods have a number of disadvantages: the need to use a large amount of organic solvents, as well as the length and cost of HPLC analysis; insufficient selectivity of UV and visible spectrophotometry. Peleshok K. et al. have developed simple, accurate, rapid, economical, accessible and validated spectrophotometric and chromatographic methods for the determination of Valsartan in binary combinations, substances and drugs. All methods have been developed in compliance with the principles of “green chemistry” and can be used for quality analysis in drug quality control laboratories and are recommended for inclusion in SPU monographs.
References
Compendium – Drugs. – Retrieved from:https:.compendium.com.ua
European Pharmacopoeia. (2023). European Pharmacopoeia (11 th edn.). Retrieved from: https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-11th-edition.
Health-ua.com: Specialized medical portal. – Retrieved from: https:.health-ua.com
Peleshok K.Ye. (2022). Development and validation of methods for the analysis of Valsartan and Atenolol in drugs. Candidate’s thesis. Ternopil: I. Horbachevsky Ternopil National Medical University [in Ukrainian].
(2015). State Pharmacopoeia of Ukraine. Supple-ment 2. Vol. 1. Kharkiv: Derzhavne pidpryiemstvo “Ukrain-skyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv” [in Ukrainian].
(2014). State Pharmacopoeia of Ukraine. Supplement 2. Vol. 2. Kharkiv: Derzhavne pidpryiemstvo “Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv” [in Ukrainian].
(2014). State Pharmacopoeia of Ukraine. Supplement 2. Vol. 3. Kharkiv: Derzhavne pidpryiemstvo “Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv” [in Ukrainian].
(2016). State Pharmacopoeia of Ukraine. Supplement 2. Ed 1. Kharkiv: Derzhavne pidpryiemstvo “Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv” [in Ukrainian].
(2018). State Pharmacopoeia of Ukraine. Supplement 2. Ed 2. Kharkiv: Derzhavne pidpryiemstvo “Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv” [in Ukrainian].
(2018). State Pharmacopoeia of Ukraine. Supplement 2. Ed 3. Kharkiv: Derzhavne pidpryiemstvo “Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv” [in Ukrainian].
(2018). European Medicine Agency. CHMP List of questions. Retrieved from: https:.www.ema.europa.eu/documents/referral/valsartan-article-31-referral-chmp-list-questions-be-addressed-api-manufacturers-valsartan_en.pdf.
French National Agency for Medicines and Health Products Safety Laboratory Controls Division – French OMCL. Determination of NDMA and NDEA in SARTAN drug substances by HPLC/UV. Method reference: 19A0416-01. Retrieved from: https:.www.edqm.eu/sites/default/files/method_19a041601_ndma_and_ndea_in_sartan_by_hplc-uv_-_ansm.pdf.
Tatar S., & Sağlık S. (2002). Comparison of UV-and second derivative-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation. Journal of Pharmaceutical and Biomedical Analysis, 30 (2), 371-375.
Pradhan, K.K., Mishra, U.S., Pattnaik, S., Panigrahi, G., Pasa G., & Sahu K.C. (2011). Stress degradation studies on valsartan and development of a validated method by UV spectrophotometric in bulk and pharmaceutical dosage form. Journal of Pharmaceutical and Biomedical Sciences, 8 (02), 1-8.
Gupta, K.R., Wadodkar, A.R., & Wadodkar, S.G. (2010). UV-Spectrophotometric methods for estimation of Valsartan in bulk and tablet dosage form. International Journal of Chem Tech Research, 2 (2), 985-989.
Tajane, T.S. (2018). Estimation of Valsartan in pharmaceutical formulation by area under curve spectrophotometric method. International Journal of Advances in Pharmaceutics, 07 (01), 01-04.
Jadhav, M.L., Girase, M.V., Tidme, S.K., & Junagade, M.S. (2014). Development and validation of spectrophotometric methods for simultaneous estimation of valsartan and hydrochlorothiazide in tablet dosage form. International Journal of Spectroscopy, 2014, Article ID 873819.
Lotfya, H.M., Hegazya, M.A., Mowaka S., & Mohamed, E.H. (2015). Novel spectrophotometric methods for simultaneous determination of Amlodipine, Valsartan and Hydrochlorothiazide in their ternary mixture. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 140, 495-508.
Kamal, A.H., Marie, A.A., & Hammad, S.F. (2020). Validated spectrophotometric methods for simultaneous determination of nebivolol hydrochloride and valsartan in their tablet. Microchemical Journal, 155, 104741.
Ramachandran, S., Mandal, B.K., & Navalgund, S.G. (2011). Simultaneous spectrophotometric determination of valsartan and Ezetimibe in pharmaceuticals. Tropical Journal of Pharmaceutical Research, 10 (6), 809-815.
Omar, M.A., Abdelmageed, O.H., Abdel-Gaber, A.A., & Abdel-Megied, A.M. (2011). Spectrophotometric and spectrofluorimetric determination of certain angiotensin receptor blockers through complex formation. Journal of Pharmaceutical Sciences and Research, 3 (10), 1499-1510.
Peleshok K., Bondar B., Kryskiw L., Kucher T., Poliak O., & Logoyda L. (2021). Non-extractive spectrophotometric determination of valsartan in pure form and in pharmaceutical products by ion-pair complex formation with bromophenol blue and methyl red. Pharmacia, 68 (4), 851-858.
Peleshok K., Poliak O., Kryskiw L., Agyemang F. Sarpong, Zarivna N., Korobko D., Zahrychuk H., Horlachuk N., Sverstiuk A., Levytska L., & Logoyda L. (2021). Development and validation of spectrophotometric method for simultaneous estimation of valsartan and atenolol in binary mixtures: aplication to tablets analysis. Pharmakeftiki, 33 (I), 52-60.
Patro, S.K., Kanungo, S.K., Patro, V.J., & Choudhury, N.S. (2010). Stability indicating RP-HPLC method for determination of valsartan in pure and pharmaceutical formulation. Journal of Chemistry, 7 (1), 246-252.
Vinzuda, D.U., Sailor, G.U., & Sheth, N.R. (2010). RP-HPLC method for determination of valsartan in tablet dosage form. International Journal of Chem Tech Research, 2 (3), 1461-1467.
Parambi, D.G.T., Mathew, M., & Ganesan V. (2011). A validated stability indicating HPLC method for the determination of Valsartan in tablet dosage forms. Journal of Applied Pharmaceutical Science, 1 (04), 97-99.
Krishnaiah, C., Reddy, A.R., Kumar, R., & Mukkanti K. (2010). Stability-indicating UPLC method for determination of Valsartan and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. Journal of Pharmaceutical and Biomedical Analysis, 53 (3), 483-489.
Ramachandran, S., Mandal, B.K., & Navalgund, S.G. (2014). Stability-indicating HPLC method for the simultaneous determination of valsartan and ezetimibe in pharmaceuticals. Tropical Journal of Pharmaceutical Research, 13 (5), 809-817.
Tian, D.F., Tian, X.L., Tian, T., Wang, Z.Y., & Mo, F.K. (2008). Simultaneous determination of valsartan and hydrochlorothiazide in tablets by RP-HPLC. Indian Journal of Pharmaceutical Sciences, 70 (3), 372-374.
Nekkala, K., Kumar, J.V.S., Ramachandran, D., Ramanaiah, G., & Srinivas, G. (2014). Method development and validation of stability indicating RP-HPLC method for simultaneous estimation of Nebivolol HCL and Valsartan in bulk and its pharmaceutical formulations. American Journal of Advanced Drug Delivery, 2 (5), 624-637.
Imam, S.S, Ahad, A., Aqil, M., Sultana, Y., & Ali, A. (2013). A validated RP-HPLC method for simultaneous determination of propranolol and valsartan in bulk drug and gel formulation. J. Pharm. Bioallied. Sci, 5 (1), 61-65.
Lakshmi, K.S., & Sivasubramanian L. (2010). A stability indicating HPLC method for the simultaneous determination of valsartan and ramipril in binary combination. Journal of the Chilean Chemical Society, 55 (2), 223-226.
Çelebier, M., Kaynak, M.S., Altınöz, S., & Sahin, S. (2010). HPLC method development for the simultaneous analysis of amlodipine and valsartan in combined dosage forms and in vitro dissolution studies. Brazilian Journal of Pharmaceutical Sciences, 46 (4), 4761-4768.
Chitlange, S.S., Bagri, K., & Sakarkar, D.M. (2008). Stability indicating RP- HPLC method for simultaneous estimation of valsartan and amlodipine in capsule formulation. Asian J. Res. Chem., 1 (1), 15-18.
Yuryeva, O., Kondratova, Y., & Logoyda, L. (2018). Development of high-performance liquid chromatography method for simultaneous analysis of amlodipine and valsartan in combined dosage form and in vitro disslotution studies. Asian Journal of Pharmaceutical and Clinical Research, 11 (5), 200-204.
Piponski, M., Peleshok, K., Logoyda, L., Kravchuk, L., Piatnochka, V., & Zakharchuk, U. (2020). Efficient Validated HPLC/UV method for determination of valsartan andatenolol in dosage form and in vitro dissolution studies. Biointerface Research in Applied Chemistry, 10 (6), 6669-6675.
Peleshok, K., Piponski, M., Ajie, E.A., Poliak, O., Zarivna, N., Denefil, O., & Logoyda, L. (2021). Novel HPLC-UV method for simultaneous determination of valsartan and atenolol in fixed dosage form; Study of green profile assessment. Pharmacia, 68 (1), 43-51.
Peleshok, K., Piponski, M., Kovalenko, S., Ahmed, H., Abdel-Megied, A., Ezike, O.F., & Logoyda, L. (2021). New liquid chromatography assays for simultaneous quantification of antihypertensives atenolol and valsartan in their dosage forms. Journal of Separation Science, 44, 565-575.
Macek, J., Klima, J., & Ptáček, P. (2006). Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. Journal of Chromatography B, 832 (1), 169-172.
Piao, Z.Z., Lee, E.S., Tran, H.T., & Lee, B.J. (2008). Improved analytical validation and pharmacokinetics of valsartan using HPLC with UV detection. Archives of Pharmacal Research, 31 (8), 1055-1059.
Koseki, N., Kawashita, H., Hara, H., Niina, M., Tanaka, M., Kawai, R., Nagae, Y., & Masuda, N. (2007). Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 43 (5), 1769-1774.
Li, H., Jiang, Y., Wang, J., Gu, J., Wang, Y., Yunbiao, T., & Zhao, L. (2007). A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 852(1-2), 436-442.
Selvan, P.S., Gowda, K.V., Mandal, U., Sam Solomon, W.D., & Pal, W.D. (2007). Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 858 (1-2), 143-150.
Peleshok K., Poliak O., Zarivna N., Oleshchuk O., Mudryk U., Hlushok V., Sverstiuk A., Svan O., Terenda N., Makhnitskyy A., Yaremchuk O., Logoyda L. (2021). LС-MS/MS method development for the quantitative determination of valsartan from Caco-2 cell monolayers: application to permeability assay. Pharmakeftiki, 33 (II), 107-115.
Peleshok, K. (2020). Quality control measurement and in vitro bioequivalence of valsartan and atenolol tablets marketed in Ukraine. International Journal of Medicine and Medical Research, 2, 52-58 [in Ukrainian].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Medical and Clinical Chemistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
